Literature DB >> 10914103

Newborn screening for cystic fibrosis in Victoria: 10 years' experience (1989-1998).

R J Massie1, M Olsen, J Glazner, C F Robertson, I Francis.   

Abstract

OBJECTIVE: To review the effectiveness of statewide newborn screening for cystic fibrosis (CF) in Victoria over the first 10 years of the program (1989-1998).
DESIGN: Population study involving screening of newborns by immunoreactive trypsinogen (IRT) testing on Day 3-5, followed by either repeat IRT testing (1989-1990) or delta F508 mutation analysis (1991-1998). PATIENTS AND
SETTING: All babies screened for CF in a newborn screening program in Victoria in 1989-1998. MAIN OUTCOME MEASURE: The diagnosis of CF.
RESULTS: Of 635,157 babies born in Victoria in the 10 years, 191 were diagnosed with CF. A further 30 cases were detected antenatally, giving an incidence of 1/2874 (95% CI, 1/2519-1/3294). CF was detected early in 182 babies (95.3% of affected babies in the screened cohort)--136 by screening, 35 because they had meconium ileus, and 11 because they were siblings of older children with CF. Nine cases of CF were missed by screening. Of these nine babies, four did not have an elevated neonatal IRT level, one had a normal IRT level at repeat testing at 4-6 weeks (1989-1990), three did not have a delta F508 mutation (1991-1998), and one had a false negative sweat test result. Six of the nine missed babies (67%) were diagnosed within four months of birth.
CONCLUSION: Newborn screening for CF in Victoria has proven effective in detecting most babies with CF in the newborn period. However, a sweat test should be requested when the clinical features suggest the diagnosis of CF, even if the child has been screened.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10914103     DOI: 10.5694/j.1326-5377.2000.tb124123.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  14 in total

1.  Impact of public health strategies on the birth prevalence of cystic fibrosis in Brittany, France.

Authors:  Virginie Scotet; Marie-Pierre Audrézet; Michel Roussey; Gilles Rault; Martine Blayau; Marc De Braekeleer; Claude Férec
Journal:  Hum Genet       Date:  2003-05-27       Impact factor: 4.132

2.  Newborn screening.

Authors:  James J Pitt
Journal:  Clin Biochem Rev       Date:  2010-05

3.  Immunoreactive trypsin levels in neonates with meconium ileus.

Authors:  L C Steven; G Gavel; D Young; R Carachi
Journal:  Pediatr Surg Int       Date:  2006-01-03       Impact factor: 1.827

4.  The relevance of sweat testing for the diagnosis of cystic fibrosis in the genomic era.

Authors:  Avantika Mishra; Ronda Greaves; John Massie
Journal:  Clin Biochem Rev       Date:  2005-11

5.  Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.

Authors:  J Massie; L Curnow; N Tzanakos; I Francis; C F Robertson
Journal:  Arch Dis Child       Date:  2005-10-21       Impact factor: 3.791

6.  Uptake of carrier testing in families after cystic fibrosis diagnosis through newborn screening.

Authors:  Belinda J McClaren; Sylvia A Metcalfe; Maryanne Aitken; R John Massie; Obioha C Ukoumunne; David J Amor
Journal:  Eur J Hum Genet       Date:  2010-05-26       Impact factor: 4.246

7.  Caregiver coping, mental health and child problem behaviours in cystic fibrosis: a cross-sectional study.

Authors:  Jane Sheehan; Harriet Hiscock; John Massie; Adam Jaffe; Margaret Hay
Journal:  Int J Behav Med       Date:  2014-04

8.  Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data.

Authors:  Yuanyuan Gu; Sonia García-Pérez; John Massie; Kees van Gool
Journal:  Eur J Health Econ       Date:  2014-08-09

9.  Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.

Authors:  Philip M Farrell; Beryl J Rosenstein; Terry B White; Frank J Accurso; Carlo Castellani; Garry R Cutting; Peter R Durie; Vicky A Legrys; John Massie; Richard B Parad; Michael J Rock; Preston W Campbell
Journal:  J Pediatr       Date:  2008-08       Impact factor: 4.406

10.  Newborn Screening for Cystic Fibrosis in Mersin Province: Yearly Assessment of the National Program.

Authors:  Ali Özdemir; Dilek Doğruel
Journal:  Turk Thorac J       Date:  2020-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.